Aimmune

Aimmune

Aimmune

Aimmune is a clinical-stage biopharmaceutical company. Our mission is to improve the lives of people with food allergies. Guidelines on our site
Founded
2011
Raised
$145M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$145,000,000
Post-IPO equity - 2016
Nestlé Health Science
Team Size
1–10
Employees
Xconomy

Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal

Reuters Top News

Nestle pays $2 billion to secure Aimmune's allergy treatment

Xconomy

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Xconomy

Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More

Xconomy

Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate

MedCity News

FDA approves Aimmune's peanut allergy drug

Xconomy

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

Xconomy , MedCity News

Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA

MedCity News , Xconomy

FDA focuses on safety in review of Aimmune's peanut allergy drug

Xconomy

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Xconomy

FDA's Gottlieb Adds Confusion to Aimmune's Claims of Shutdown Delay

Xconomy

Government Shutdown Hits Biotech as FDA Punts Review of Aimmune Drug

$145,000,000 Post-IPO equity
businesswire

Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment...

Xconomy

Aimmune Prices Upsized $160M IPO, Climbs Higher in Debut

Health Funding
Xconomy

Aimmune May Seek Up To $115M in IPO for Allergy Therapy Drug

Health